Literature DB >> 21178786

Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems.

Gabriele Di Comite1, Alberto Morganti.   

Abstract

Chromogranin A (CHGA) is a secretory protein stored in and released from neurons and cells of the diffuse neuroendocrine system. Cells of the adrenal medulla and adrenergic terminals are a main source of CHGA but also myocardial cells produce it under stress conditions. After secretion, CHGA is cleaved into several biologically active fragments, including vasostatins and catestatin. CHGA and its proteolytic peptides exert a broad spectrum of activities on the cardiovascular system. They act on blood pressure by controlling the vascular tone and the cardiac inotropic and chronotropic function. CHGA revealed to be a sensitive marker of myocardial dysfunction, with a high predictive power of morbidity and mortality in heart failure and ischemic heart disease. In addition, CHGA has been involved in the control of sustained endothelial inflammation and has been shown to be a good marker of persistent vascular inflammation in rheumatologic disorders affecting vessels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178786     DOI: 10.1097/HJH.0b013e328341a429

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 2.  Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.

Authors:  Roland Baron; Eric Hesse
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

Review 3.  Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction.

Authors:  Roxana Mihaela Chiorescu; Roxana-Daiana Lazar; Sándor-Botond Buksa; Mihaela Mocan; Dan Blendea
Journal:  Front Cardiovasc Med       Date:  2022-06-17

4.  Chromogranin-A production and fragmentation in patients with Takayasu arteritis.

Authors:  Enrico Tombetti; Barbara Colombo; Maria Chiara Di Chio; Silvia Sartorelli; Maurizio Papa; Annalaura Salerno; Enrica Paola Bozzolo; Elisabetta Tombolini; Giulia Benedetti; Claudia Godi; Chiara Lanzani; Patrizia Rovere-Querini; Alessandro Del Maschio; Alessandro Ambrosi; Francesco De Cobelli; Maria Grazia Sabbadini; Elena Baldissera; Angelo Corti; Angelo A Manfredi
Journal:  Arthritis Res Ther       Date:  2016-08-17       Impact factor: 5.156

5.  Biological function and clinical relevance of chromogranin A and derived peptides.

Authors:  Maria Angela D'amico; Barbara Ghinassi; Pascal Izzicupo; Lamberto Manzoli; A Di Baldassarre
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

6.  Alteration of Endothelin 1, MCP-1 and Chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation.

Authors:  K Lackermair; S Clauss; T Voigt; I Klier; C Summo; B Hildebrand; T Nickel; H L Estner; S Kääb; R Wakili; U Wilbert-Lampen
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

7.  Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Authors:  Thor Ueland; Lars Gullestad; Lei Kou; Pål Aukrust; Inderjit S Anand; Marianne Nordlund Broughton; John J McMurray; Dirk J van Veldhuisen; David J Warren; Nils Bolstad
Journal:  ESC Heart Fail       Date:  2018-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.